

**SENATE
STATE OF MINNESOTA
NINETY-THIRD SESSION**

S.F. No. 4147

(SENATE AUTHORS: MANN, Boldon, Kunesh and Pha)

DATE	D-PG	OFFICIAL STATUS
02/22/2024	11718	Introduction and first reading Referred to Health and Human Services
02/26/2024	11826	Authors added Boldon; Kunesh
04/15/2024	13900	Author added Pha

1.1 A bill for an act

1.2 relating to health; amending the prescription drug price transparency act; requiring

1.3 wholesale drug distributors to provide information by month in the annual report;

1.4 amending Minnesota Statutes 2023 Supplement, section 62J.84, subdivision 14.

1.5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 Section 1. Minnesota Statutes 2023 Supplement, section 62J.84, subdivision 14, is amended

1.7 to read:

1.8 Subd. 14. **Wholesale drug distributor prescription drug substantial public interest**

1.9 **reporting.** (a) Beginning January 1, 2024, a wholesale drug distributor must submit to the

1.10 commissioner the information described in paragraph (b) for any prescription drug included

1.11 in a notification to report issued to the wholesale drug distributor by the department under

1.12 subdivision 10.

1.13 (b) For each of the drugs described in paragraph (a), the wholesale drug distributor shall

1.14 submit to the commissioner no later than 60 days after the date of the notification to report,

1.15 in the form and manner prescribed by the commissioner, the following information, if

1.16 applicable:

1.17 (1) a description of the drug with the following listed separately:

1.18 (i) the national drug code;

1.19 (ii) the product name;

1.20 (iii) the dosage form;

1.21 (iv) the strength; and

- 2.1 (v) the package size;
- 2.2 (2) the number of units of the drug product acquired each month by the wholesale drug
2.3 distributor during the 12-month period prior to the date of the notification to report;
- 2.4 (3) the total spent before rebates each month by the wholesale drug distributor to acquire
2.5 the drug product during the 12-month period prior to the date of the notification to report;
- 2.6 (4) the total rebate receivable amount accrued each month by the wholesale drug
2.7 distributor for the drug product during the 12-month period prior to the date of the notification
2.8 to report;
- 2.9 (5) the number of units of the drug product sold each month by the wholesale drug
2.10 distributor during the 12-month period prior to the date of the notification to report;
- 2.11 (6) gross revenue from sales in the United States generated each month by the wholesale
2.12 drug distributor for this drug product during the 12-month period prior to the date of the
2.13 notification to report; and
- 2.14 (7) total rebate payable amount accrued each month by the wholesale drug distributor
2.15 for the drug product during the 12-month period prior to the date of the notification to report.
- 2.16 (c) The wholesale drug distributor may submit any documentation necessary to support
2.17 the information reported under this subdivision.